Cholesterol reducing agents inhibit assembly of type I parainfluenza viruses

Virology. 2017 Jan 15:501:127-135. doi: 10.1016/j.virol.2016.11.011. Epub 2016 Dec 2.

Abstract

Many enveloped RNA viruses utilize lipid rafts for the assembly of progeny virions, but the role of cholesterol, a major component of rafts, on paramyxovirus budding and virion formation is controversial. In this study, we analyzed the effects of FDA-approved cholesterol-reducing agents, gemfibrozil and lovastatin, on raft formation and assembly of human parainfluenza virus type 1 (hPIV1) and Sendai virus (SeV). Treatment of the human airway epithelial A549 cells with the agents, especially when combined, significantly decreased production of infectious hPIV1 and SeV. Mechanistic analysis indicated that depletion of cellular cholesterol reduced cell surface accumulation of envelope glycoproteins and association of viral matrix and nucleocapsids with raft membrane, which resulted in impaired virus budding and release from the cells. These results indicate that cellular cholesterol is required for assembly and formation of type 1 parainfluenza viruses and suggest that cholesterol could be an attractive target for antiviral agents against hPIV1.

Keywords: Antiviral therapy; Assembly; Cholesterol; Lipid rafts; Type I parainfluenza virus.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Cell Membrane / metabolism
  • Cell Membrane / virology
  • Cholesterol / metabolism*
  • Humans
  • Parainfluenza Virus 1, Human / drug effects*
  • Parainfluenza Virus 1, Human / genetics
  • Parainfluenza Virus 1, Human / physiology
  • Paramyxoviridae Infections / drug therapy
  • Paramyxoviridae Infections / metabolism
  • Paramyxoviridae Infections / virology*
  • Protein Transport
  • Viral Proteins / genetics
  • Viral Proteins / metabolism
  • Virus Assembly / drug effects*
  • Virus Release / drug effects

Substances

  • Anticholesteremic Agents
  • Viral Proteins
  • Cholesterol